SI-BONE, Inc. (NASDAQ:SIBN) Receives Average Rating of “Buy” from Brokerages

Shares of SI-BONE, Inc. (NASDAQ:SIBN) have earned a consensus rating of “Buy” from the six brokerages that are covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $23.00.

A number of research analysts recently issued reports on SIBN shares. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price objective on shares of SI-BONE in a report on Wednesday, November 20th. Truist Financial raised their price target on shares of SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th.

Insider Buying and Selling at SI-BONE

In related news, insider Anthony J. Recupero sold 3,937 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $12.60, for a total transaction of $49,606.20. Following the completion of the sale, the insider now owns 228,554 shares of the company’s stock, valued at $2,879,780.40. This trade represents a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Anshul Maheshwari sold 5,304 shares of SI-BONE stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total value of $73,778.64. Following the completion of the sale, the chief financial officer now owns 189,319 shares of the company’s stock, valued at approximately $2,633,427.29. The trade was a 2.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 27,348 shares of company stock valued at $356,349. 3.90% of the stock is currently owned by company insiders.

Institutional Trading of SI-BONE

Several large investors have recently modified their holdings of SIBN. Harbor Capital Advisors Inc. boosted its stake in SI-BONE by 35.5% during the fourth quarter. Harbor Capital Advisors Inc. now owns 841,045 shares of the company’s stock worth $11,791,000 after acquiring an additional 220,555 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of SI-BONE by 14.7% during the third quarter. JPMorgan Chase & Co. now owns 177,793 shares of the company’s stock valued at $2,486,000 after purchasing an additional 22,732 shares during the period. Franklin Resources Inc. boosted its position in shares of SI-BONE by 9.4% during the 3rd quarter. Franklin Resources Inc. now owns 20,220 shares of the company’s stock worth $265,000 after purchasing an additional 1,745 shares in the last quarter. Barclays PLC grew its stake in shares of SI-BONE by 190.8% in the 3rd quarter. Barclays PLC now owns 96,623 shares of the company’s stock valued at $1,350,000 after buying an additional 63,402 shares during the period. Finally, Geode Capital Management LLC increased its position in SI-BONE by 3.4% in the 3rd quarter. Geode Capital Management LLC now owns 924,044 shares of the company’s stock valued at $12,921,000 after buying an additional 30,005 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

SI-BONE Price Performance

Shares of SIBN opened at $13.72 on Friday. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The stock has a market cap of $575.39 million, a PE ratio of -14.91 and a beta of 1.16. SI-BONE has a 12-month low of $11.70 and a 12-month high of $21.64. The business has a 50-day simple moving average of $13.68 and a two-hundred day simple moving average of $14.20.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.